Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance

Authors:

Abstract
Approximately 15% of patients with ovarian cancer have a germline BRCA (gBRCA) variation,1 which has important implications, including increased sensitivity to platinum-based chemotherapy and poly(ADP-ribose) polymerase inhibitors and improved survival.2 Testing first-degree relatives is also cost-effective cancer prevention.3 Since 2010, guidelines have recommended universal testing in ovarian cancer. However, testing rates are reportedly between 10% and 30%,4 and few studies have examined commercially insured populations or identified patient-, physician-, and practice-level characteristics associated with testing rates.